Synthetic triterpenoids CDDO (RTA 401) and CDDO-Me (RTA 402) inhibit HER2-driven growth of breast cancer in vivo.

被引：0
|
作者：
Konopleva, M
Zhang, WG
Ling, XY
Samudio, I
Shi, YX
McQueen, T
Tsao, T
Meyer, C
Munsell, MF
Yu, DH
Safe, SH
Hung, MC
Andreeff, M
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Reata Pharmaceut Inc, Dallas, TX USA
[3] Texas A&M Univ, College Stn, TX USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9151S / 9151S
页数：1
相关论文
共 9 条
  • [1] A180 RTA 401 (CDDO) and RTA 402 (CDDO-Me), promising new agents for mucositis.
    Meyer, CJ
    Ferguson, DA
    Watkins, B
    Fey, E
    Sonis, S
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9008S - 9008S
  • [2] RTA 401 (CDDO) and RTA 402 (CDDO-Me), promising new anti-cancer agents that also prevent oral mucositis
    Meyer, C.
    Ferguson, D.
    Watkins, B.
    Fey, E.
    Sonis, S.
    EJC SUPPLEMENTS, 2006, 4 (12): : 162 - 162
  • [3] CDDO-Me (RTA 402) is effective as single agent and in combination therapy in the 4T1 in vivo model of breast cancer.
    Ferguson, DA
    Ling, XY
    Meyer, CJ
    Marty, J
    Wick, M
    McQueen, T
    Frolova, C
    Konopleva, M
    Andreeff, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9153S - 9153S
  • [4] Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies.
    Hong, David
    Kurzrock, Razelle
    Supko, Jeffrey G.
    Lawrence, Donald
    Wheeler, Jennifer
    Eder, Joseph P.
    Ng, Chaan
    Mier, James
    Konopleva, Marina
    Konoplev, Sergej
    Ekmekcioglu, Suhenclan
    Andreeff, Michael
    Grimm, Elizabeth A.
    Kufe, Donald
    Meyer, Colin J.
    Shapiro, Geoffrey I.
    Dezube, Bruce J.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3458S - 3459S
  • [5] Interim results of a phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies
    Dezube, B. J.
    Kurzrock, R.
    Eder, J. P.
    Supko, J. G.
    Meyer, C. J.
    Camacho, L. H.
    Andreeff, M.
    Konopleva, M.
    Lescale-Matys, L.
    Hong, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Preclinical pharmacokinetic, tissue distribution, and metabolism studies of RTA 402 (CDDO-ME), a novel agent with anti-cancer and anti-inflammatory activities in phase 1 development
    Meyer, C.
    Abrahams, R.
    EJC SUPPLEMENTS, 2006, 4 (12): : 70 - 71
  • [7] Bardoxolone Methyl (CDDO-Me or RTA402) Induces Paraptosis Through Reactive Oxygen Species-mediated Endoplasmic Stress and Intracellular Calcium Release in Human Colorectal Cancer HCT-116 Cells
    Rehman, Mati Ur
    Zhao, Qing-Li
    Refaat, Alaa
    Jawaid, Paras
    Sakurai, Hiroaki
    Saitoh, Jun-ichi
    Kondo, Takashi
    Noguchi, Kyo
    FREE RADICAL BIOLOGY AND MEDICINE, 2019, 145 : S75 - S75
  • [8] Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells
    Wang, Xin-Yu
    Zhang, Xue-Hong
    Peng, Li
    Liu, Zheng
    Yang, Yin-Xue
    He, Zhi-Xu
    Dang, Hong-Wan
    Zhou, Shu-Feng
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2017, 9 (10): : 4652 - 4672
  • [9] 2-cyano-3,12 dioxooleana-1,9 diene-28-imidazolide (CDDO-Im) and 2-cyano-3,12 dioxooleana-1,9 diene-28-methyl ester (CDDO-Me) induce caspase-independent cell death in pancreatic cancer in vitro and prevent the growth of pancreatic cancer xenografts in vivo.
    Samudio, I
    Konopleva, M
    Hail, N
    Shi, YX
    McQueen, T
    Hsu, T
    Evans, R
    Meyer, C
    Honda, T
    Gribble, GW
    Sporn, M
    Gilbert, HF
    Safe, S
    Andreeff, M
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9150S - 9150S
1